Continuous Infusions Vs Scheduled Bolus Infusions
Launched by STANFORD UNIVERSITY · Jul 25, 2017
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different ways of delivering pain relief after surgery: continuous infusions and scheduled bolus infusions. Continuous infusions provide a steady flow of medication to manage pain, while bolus infusions deliver larger doses at specific times. The goal is to see which method works better for controlling pain after surgery.
To be eligible for this trial, participants need to be adults aged 65 to 74 who are having a surgical procedure and are in stable health (categories I, II, or III according to a specific health classification system). Those who are pregnant, under 18, have certain health issues, or take high doses of pain medication before surgery may not be able to join. Participants in the trial can expect to receive one of the two pain relief methods and will be closely monitored to see how well it works for them. This trial is currently recruiting, which means they are looking for volunteers to take part in the study.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Enrollment will be offered to adult patients with ASA physical status I, II, or III, presenting for nerve block catheters for post-operative analgesia.
- • -
- • Exclusion Criteria: Exclusion criteria will include: pregnancy, incarceration, age \<18, BMI \>35, pre-operative opioid use \>30 mg morphine equivalents per day, inability to communicate with investigators by telephone, and pre-existing neuropathy of the operative extremity.
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stanford, California, United States
Patients applied
Trial Officials
Jean Louis-Horn, MD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials